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OBJECTIVE The authors sought to describe the long-term recurrence patterns, prognostic factors, and effect of adjuvant or salvage radiotherapy (RT) on treatment outcomes for patients with spinal myxopapillary ependymoma (MPE).
METHODS The authors reviewed a tertiary institution IRB-approved database and collected data regarding patient,
tumor, and treatment characteristics for all patients treated consecutively from 1974 to 2015 for histologically confirmed
spinal MPE. Key outcomes included relapse-free survival (RFS), postrecurrence RFS, failure patterns, and influence of
timing of RT on recurrence patterns. Cox proportional hazards regression and Kaplan-Meier analyses were utilized.
RESULTS Of the 59 patients included in the study, the median age at initial surgery was 34 years (range 12–74 years),
30 patients (51%) were female, and the most common presenting symptom was pain (n = 52, 88%). Extent of resection
at diagnosis was gross-total resection (GTR) in 39 patients (66%), subtotal resection (STR) in 15 (25%), and unknown in
5 patients (9%). After surgery, 10 patients (17%) underwent adjuvant RT (5/39 GTR [13%] and 5/15 STR [33%] patients).
Median follow-up was 6.2 years (range 0.1–35.3 years). Overall, 20 patients (34%) experienced recurrence (local, n =
15; distant, n = 5). The median RFS was 11.2 years (95% CI 77 to not reached), and the 5- and 10-year RFS rates were
72.3% (95% CI 59.4–86.3) and 54.0% (95% CI, 36.4–71.6), respectively.
STR was associated with a higher risk of recurrence (HR 6.45, 95% CI 2.15–19.23, p < 0.001) than GTR, and the median
RFS after GTR was 17.2 years versus 5.5 years after STR. Adjuvant RT was not associated with improved RFS, regardless of whether it was delivered after GTR or STR. Of the 20 patients with recurrence, 12 (60%) underwent salvage treatment with surgery alone (GTR, n = 6), 4 (20%) with RT alone, and 4 (20%) with surgery and RT. Compared to salvage
surgery alone, salvage RT, with or without surgery, was associated with a significantly longer postrecurrence RFS (median 9.5 years vs 1.6 years; log-rank, p = 0.006).
CONCLUSIONS At initial diagnosis of spinal MPE, GTR is key to long-term RFS, with no benefit to immediate adjuvant
RT observed in this series. RT at the time of recurrence, however, is associated with a significantly longer time to second
disease recurrence. Surveillance imaging of the entire neuraxis remains crucial, as distant failure is not uncommon in
this patient population.
https://thejns.org/doi/abs/10.3171/2020.2.SPINE191534
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myxopapillary ependymomas (MPEs) represent a clinically and biologically distinct subset of
ependymomas, which are WHO grade I and tend
to occur in the conus medullaris, cauda equina, and/or
filum terminale. These tumors are rare, with a reported
pinal

incidence of 1 per million person-years, and have a slight
predominance in males and Caucasians.1 The natural history of spinal MPE is long, with reported 10-year overall
and progression-free survival rates of 92% and 61%, respectively.2

ABBREVIATIONS GTR = gross-total resection; MDACC = MD Anderson Cancer Center; MPE = myxopapillary ependymoma; RFS = relapse-free survival; RT = radiotherapy; STR = subtotal resection.
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Owing to the rarity of spinal MPEs, the optimal management remains unclear. Retrospective studies suggest
that gross-total resection (GTR) is the most important
factor in achieving long-term disease control.2–4 The role
of adjuvant radiotherapy (RT) is less clear, with some
studies suggesting benefit to upfront combined modality
treatment regardless of the extent of resection.2,3,5–7 The
objective of the current study was to assess the long-term
clinical outcomes of consecutive patients managed at our
institution, as well as to analyze recurrence patterns, prognostic factors, and the effect of adjuvant or salvage RT.

Methods

We queried an IRB-approved database at our tertiary
institution for all patients with histologically confirmed
spinal MPE treated consecutively between 1974 and 2015.
Patient characteristics, tumor location and details, and
treatment course at initial diagnosis and relapse, as well
as all disease outcomes, were abstracted from the shared
medical record.
All resections were piecemeal, owing to the difficulty
in removing MPE in an en bloc fashion and the institutional practice at the time. Extent of resection was defined
as either GTR or subtotal resection (STR), based on surgeon assessment rather than postoperative imaging due
to the difficulty in distinguishing residual disease from
postoperative changes. RT was delivered following primary resection or at disease recurrence, at the discretion
of the treating physicians. RT was delivered via an external beam approach, using various techniques, such as 2D
anterior-posterior fields, 3D conformal RT, and intensitymodulated RT, based on era of treatment and physician
discretion.
The primary endpoint was relapse-free survival (RFS),
calculated from the date of initial surgery to either the
date of imaging confirmation of recurrence or the date of
last clinical follow-up for patients who did not experience
recurrence of their disease. The secondary endpoint was
postrecurrence RFS, which was calculated from the date
of initial recurrence to the date of subsequent recurrence
or the date of last clinical follow-up for patients who did
not experience a second recurrence.
Statistical Analysis
Cox proportional hazards regression was used to identify clinical factors associated with RFS on univariate
analysis, as well as multivariable analysis when appropriate. The Kaplan-Meier method was used to estimate survival, and the log-rank test was used to compare survival
curves. Statistical analysis was performed using SAS v9.4
(SAS Institute), and p values < 0.05 were considered statistically significant.

Results

The patient characteristics of the 59 patients who met
inclusion criteria for this study are summarized in Table
1. The median age at initial surgery was 34 years (range
12–74 years), and 30 patients (51%) were female. The most
common symptoms at initial presentation were pain in

TABLE 1. Patient and treatment characteristics
Characteristic
Age, yrs
≤35
>35
Karnofsky Performance Scale score
≥70
<70
Sex
Female
Male
Symptoms at presentation
Pain
Numbness
Weakness
Abnormal gait
Urinary incontinence
Bowel incontinence
Tingling
Extent of resection at initial surgery
GTR
STR or biopsy
Not documented
Adjuvant RT after initial surgery
No
Yes
Any recurrence after initial surgery
No
Yes
Salvage treatment for initial recurrence
RT alone
RT and surgery
Surgery alone

No. (%)
33 (56)
26 (44)
53 (90)
6 (10)
30 (51)
29 (49)
52 (88)
15 (25)
10 (17)
9 (15)
6 (10)
5 (8)
2 (3)
39 (66)
15 (25)
5 (9)
49 (83)
10 (17)
39 (66)
20 (33)
4 (20)
4 (20)
12 (60)

52 patients (88%), numbness in 15 (25%), weakness in 10
(17%), and abnormal gait in 9 patients (15%). A majority of
patients underwent MRI for diagnosis (43 patients, 85%)
and the remainder had a combination of myelograms along
with other diagnostic imaging, with 2 patients (3.4%) assessed with CT only. Two-thirds of patients (n = 39, 66%)
in this series were diagnosed with disease in the lumbosacral region, and the remainder of patients (n = 20, 34%)
had disease in the thoracic spine.
Extent of resection at diagnosis was GTR in 39 (66%),
STR in 15 (25%), and unknown in 5 (9%) patients. After
the initial surgery, 10 patients (17%) underwent adjuvant
RT (5 patients after GTR and 5 patients after STR) to a
median dose of 49 Gy (range 45–58 Gy) delivered via conventional fractionation. Of these 10 patients, 7 had disease
in the lumbosacral region and 3 had disease in the thoracic
region. At last follow-up, 9 patients (15%) had experienced
a single recurrence, 7 (12%) had 2 recurrences, 2 patients
(34%) had 3 recurrences, and 2 patients (34%) had 4 recurrences.
J Neurosurg Spine Volume 33 • September 2020
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FIG. 1. RFS of all patients.

Median follow-up from time of initial surgery was 6.2
years (range 0.1–35.3 years). Overall, 20 patients (34%) experienced disease recurrence (local, n = 15; distant, n = 5).
Among all patients, the median RFS was 11.2 years (95%
CI 7.7 to not reached), and the 5- and 10-year RFS rates
were 72.8% (95% CI 59.4–86.3) and 54.0% (95% CI 36.4–
71.6), respectively (Fig. 1). The median survival time from
initial surgery was 6.6 years (range 0.1–35.3 years), and at
the time of this analysis 54 patients (92%) were alive and
continued to be followed.
On univariate analysis (Table 2), STR was associated
with a higher risk of disease recurrence (HR 6.45, 95% CI
2.15–19.23, p < 0.001) compared to GTR. The 5-year RFS
after GTR was 81.6% (95% CI 66.6–96.7) versus 50.7%
(95% CI 21.9–79.6) after STR (log-rank, p < 0.001; Fig. 2).
Among all patients, adjuvant RT was not associated with
improved RFS (log-rank, p = 0.97; Fig. 3). When analyzed
separately by the type of resection, adjuvant RT was not
associated with improved RFS after either GTR (log-rank,
p = 0.92) or STR (log-rank, p = 0.27). Age ≤ 35 years,
disease location within the spine (i.e., thoracic vs lumbosacral), and adjuvant RT dose ≥ 50 Gy were not associated
with RFS (p > 0.05 for each).
Overall, 20 patients (34%) had a recurrence: 15 patients (75% of this subgroup) had a local recurrence and
5 patients (25% of this subgroup) had a distant recurrence
(recurrence at a different spinal segment). At the time of
recurrence, 12 patients (60%) subsequently underwent salvage treatment with surgery alone (GTR, n = 6), 4 (20%)
with RT alone, and 4 patients (20%) with both surgery and

FIG. 2. RFS stratified by extent of resection. Figure is available in color
online only.

RT. Compared to salvage surgery alone, salvage RT with
or without surgery was associated with a significantly longer postrecurrence RFS (median 9.5 years vs 1.6 years;
log-rank, p = 0.006; Fig. 4 upper). The 5-year postrecurrence RFS was 27.5% (95% CI 1.1–54.0) versus 84.6%
(95% CI 56.9–100) for patients treated with surgery alone
versus RT, with or without surgery, respectively. We separately analyzed the subset of patients who were treated
with surgery alone at first diagnosis but who received RT
(with or without surgery) at the time of disease relapse (n
= 8). For these patients, there was a trend to improvement
in time to next recurrence in the salvage setting exceeding
the disease-free interval observed from initial diagnosis
(median 9.5 vs 2.9 years; log-rank, p = 0.061; Fig. 4 lower).
Of the patients who received salvage RT (with or without
surgery), none had received prior RT. No other clear selection bias for the choice of salvage treatment was noted
with regard to initial extent of resection, recurrence location (distant vs local), extent of resection at recurrence,
RFS, or age at recurrence (Supplemental Tables 1 and 2).
Of the 5 patients with initial distal recurrence, 2 had re-

TABLE 2. Univariate analysis for RFS
Factor

p Value

HR (95% CI)

Age, yrs (>35 vs ≤35)
STR vs GTR (n = 54)
T spine vs LS spine
Adjuvant RT (no vs yes)
Dose (<50 vs ≥50 Gy, n = 10)

0.49
<0.001
0.66
0.97
0.15

1.37 (0.56–3.40)
6.45 (2.15–19.23)
1.24 (0.48–3.21)
1.02 (0.34–3.09)
0.17 (0.01–1.92)

LS = lumbosacral; T = thoracic.
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FIG. 3. RFS stratified by treatment with adjuvant RT. Figure is available
in color online only.
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FIG. 4. Upper: RFS after salvage stratified by treatment with RT.
Lower: RFS for patients treated with surgery alone and who received
RT at the time of relapse; the same patients are plotted on both survival
curves. Figure is available in color online only.

ceived initial adjuvant RT (GTR, n = 1; STR, n = 1), while
the other 3 had received initial surgery alone (GTR, n =
2; STR, n = 1). Distal failure was located in the inferioradjacent cord in 2 patients, inferior-nonadjacent cord in
1, superior-adjacent cord in 0, and superior-nonadjacent
cord in 2 patients. Of the 15 patients with an initial local
recurrence, 2 had received adjuvant RT while the remainder received initial surgery alone. Two of these patients
went on to a subsequent distant recurrence: 1 patient in
the superior-nonadjacent cord and 1 patient in the brain
(nonadjacent).

Discussion

Management of spinal MPE represents a unique clinical challenge owing to the difficulty in achieving a complete en bloc resection, disease- and treatment-related
morbidity associated with anatomical location, risk of locoregional and distant recurrence, rarity of this disease,
and the relatively young age at disease presentation. Given
the paucity of data in the literature with significant heterogeneity among analyses, additional data are sorely needed.
Our present study of spinal MPE identified several key
findings which supplement our understanding of this rare
disease. First, initial GTR offers the best chance of cure,
and has better outcomes than upfront combined modality

therapy. Second, adjuvant RT after initial surgery is not
associated with improved RFS. However, RT salvage therapy is associated with significant and dramatic improvements and prevention of a second disease relapse. Lastly,
given the long-term follow-up in this series, we demonstrated that up to one-fourth of patients suffer treatment
failure elsewhere in the spine, a finding that highlights the
potential for late neuraxis failure in these patients.
Resection is the primary management strategy for
spinal MPE, and GTR is associated with significantly
improved disease outcomes.2,4,8 The frequency of GTR
varies between 27% and 100% in the literature, and the
data presented in our study demonstrate a clear benefit in
terms of RFS with aggressive upfront GTR.8 Of course,
in general, no surgeon undertakes a deliberate STR when
a GTR is feasible, and therefore, even a definitive conclusion regarding GTR versus STR is difficult to promulgate
in such a retrospective series. In our initial analysis of 37
patients with spinal MPE published in 2011, GTR demonstrated a numerically improved median RFS of 11.2 years
compared to 5.5 years with STR, results which did not
meet statistical significance (log-rank, p = 0.075).9 However, in the present study with updated analysis, additional
patients, and longer follow-up, GTR was associated with
a statistically significant improvement in median RFS of
17.2 years compared to 5.5 years with STR. These data
are consistent with the largest series of spinal MPE patients, performed using pooled data from MD Anderson
Cancer Center (MDACC) and the Rare Cancer Network,
which demonstrated in multivariable analysis that STR
was associated with adverse local control (LC; HR 2.08,
95% CI 1.13–3.82, p = 0.01) and progression-free survival
(HR 2.14, 95% CI 1.38–4.24, p = 0.02).2 An older study
similarly demonstrated that GTR was associated with improved overall survival (OS; median 19 years with GTR
vs 14 years with STR).4 Furthermore, a large review of the
literature with aggregated data from 1602 patients demonstrated a strong association with GTR and improved OS at
5 and 10 years.8 Together, these data collectively highlight
the importance of obtaining a radical complete resection
of spinal MPE and support the role of multidisciplinary
management and specialized surgical expertise among
newly diagnosed patients.
The role of adjuvant RT following initial resection is
controversial, as this has never been prospectively evaluated in a randomized controlled manner, and consequently,
the literature contains predominantly single-institutional
retrospective series. All of these series span very long
eras, and therefore the imaging, surgical, and radiotherapeutic techniques are extremely heterogeneous. Although
reports in the literature have generally demonstrated improved outcomes with the use of immediate adjuvant RT,
none of the retrospective series utilize predefined criteria
for selecting adjuvant RT, thereby introducing enormous
bias and making data interpretation even more complicated.2,3,5–7 An initial report from MDACC described the outcomes of 51 patients with spinal MPE and demonstrated
that adjuvant RT significantly improved local control (LC)
after STR (10-year LC was 0% after STR alone vs 65%
with adjuvant RT, p = 0.008), as well as following GTR
(median LC was 4.75 years after GTR alone vs 10.5 years
J Neurosurg Spine Volume 33 • September 2020
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with adjuvant RT, p = 0.03). These data were subsequently combined in a larger pooled analysis of 183 patients
with spinal MPE by Weber and colleagues,2 in which 47%
of patients received adjuvant RT. In their multivariable
analysis, after accounting for age, extent of resection, and
metastasis at diagnosis, treatment with surgery and adjuvant RT was associated with both improved LC (standarddose RT: HR 0.34, 95% CI 0.15–0.77; high-dose RT: HR
0.34, 95% CI 0.16–0.71; p < 0.001) and progression-free
survival (standard-dose RT: HR 0.28, 95% CI 0.12–0.60;
high-dose RT: HR 0.28, 95% CI 0.14–0.57; p < 0.001).
Ten-year progression-free survival was 70% with adjuvant RT compared to < 40% with surgery alone, but no
differences were specifically reported regarding extent of
resection and effect of RT.2 In contrast, we found no significant benefit in RFS with adjuvant RT in both the initial and present analysis, regardless of extent of resection.9
Although both studies had similar follow-up periods and
roughly the same proportion of patients achieving GTR
(54%–66%), key differences in selection criteria for adjuvant RT in both centers may lead to significant selection
bias. For example, of the 10 patients treated with adjuvant
RT in this series, 5 had a GTR, whereas one-third of STR
patients (the remaining 5 patients) received adjuvant RT.
Therefore, our series could have limited power for demonstrating the benefit given that half of the patients who received adjuvant treatment received it after GTR and therefore were in the group least likely to benefit from RT. This
hypothesis was bolstered by the finding that after enriching the group with patients treated with adjuvant RT at recurrence, the benefit of RT was more easily demonstrated.
Therefore, high-risk groups (STR or questionable GTR)
should still be evaluated and considered for postoperative RT given the risk of disease recurrence and potential
benefits of adjuvant treatment. It is important to note that
pediatric patients were not well represented in this series,
and as other series demonstrate a higher risk of recurrence
in the pediatric population, even in the setting of GTR, our
results should not be extrapolated to pediatric patients.10
A unique finding from our series is that at first recurrence, treatment with RT improves median RFS by almost
8 years, from 1.6 years with surgery alone to 9.5 years with
the addition of RT. Thus, our data suggest that for patients
who do not receive RT in the adjuvant setting, salvage RT
is crucial in reducing the risk of further recurrence, even
after salvage GTR. Although we were unable to report
toxicity data, Weber and colleagues demonstrated a trend
toward increased late adverse events with surgery plus RT
compared with surgery alone (43.9% vs 56.1%, respectively; p = 0.07).2 However, in light of recent advances in RT
techniques that minimize the dose to surrounding critical
structures and associated toxicity, such as proton therapy,
the therapeutic ratio may shift to favor upfront adjuvant
therapy as opposed to salvage treatment.11–15 Molecular
characterization of these tumors is key to shedding some
light as to whether there are distinct molecular entities
which are likely to recur, as patients in this series experienced up to 4 episodes of disease relapse, despite similar
initial pathologies.
Distant spinal failure as a component of disease recurrence is relatively common. In our series, 25% of failures
396

were distant. No obvious trend emerged regarding the location of distant failures as they were found to be located
either adjacent, nonadjacent, cranial, or caudal to the site
of initial disease. In the study by Weber and colleagues,
29% had distant spine failure and 19% had brain failure.2
A recent series of 19 patients reported that 58% of patients
had distant disease, 36% of which was present at diagnosis.16 Weber et al. further note that given the indolent
clinical course of asymptomatic distant disease, close observation is a reasonable strategy. Given the high rates of
distant failure, surveillance imaging of the entire neuraxis
is a crucial component of disease management.
Study Limitations
It is important to note the limitations of the current
analysis, including its retrospective nature and small sample size. Because the study spanned 4 decades, advances
in imaging (CT to MRI), surgery, and RT (3D conformal
to intensity-modulated RT) occurred. Management was
subject to selection bias and follow-up schedules were
inconsistent. Treatment outcomes outside of recurrencespecific data, such as recovery from surgery or presence
or absence of neurological deficits at the time of initial
surgery or at disease relapse, would be useful to include
given the comparison across modalities (surgery with or
without RT); however, these variables were not studied in
this analysis. Additionally, we were unable to report toxicity data. Despite these limitations, our data represent an
important contribution to the literature for this rare entity,
given the long-term follow-up and meticulous assessment
of initial surgery and recurrence patterns, which cannot
easily be performed in larger database studies.

Conclusions

Owing to the relatively young age at presentation and
long natural history of spinal MPE, our findings support
aggressive initial surgical resection to provide the longest
recurrence-free interval and highlight the benefit of RT at
the time of salvage for those patients treated with surgery
alone in the upfront setting. Surveillance imaging of the
entire neuraxis is crucial as distant failure is not uncommon.
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